

OF THE NATIONAL ACADEMIES

The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: A

Workshop

Keck Center of the National Academy of Sciences, 500 Fifth St. NW

Washington, DC

June 8th, 2015		
7:30 am	Registration and Breakfast	
8:00 am	Welcome from the National Cancer Policy Forum	
	Overview of the Workshop	
	Michael Kastan (Duke)	
	Planning Committee Chair	
8:15	Session 1: Overview and value of trials that include pets in translational cancer research	
	Moderator: Michael Kastan, Duke University	
	Overview of current challenges and opportunities in oncology drug development	
	Lee Helman, National Cancer Institute	
	Strengths and limitations of traditional pre-clinical models	
	Beverly Teicher, National Cancer Institute	
	Advantages and experiences with trials that include animal patients	
	Chand Khanna, National Cancer Institute	
	Group Discussion	
10:10	Break	
10:20	Session 2: Canine tumor biology and genomics informing cancer drug development	
	Moderator: Deborah Knapp, Purdue University	
	The summer of the of service down and the service of the interviews	
	The current state of canine tumor genetics and scientific limitations Heidi Parker, National Institutes of Health/National Human Genome Research Institute	
	Ticki Farker, National Institutes of Treatily National Human Octobile Research Institute	
	Use and availability of canine cancer tissue banks in translational research	
	Matthew Breen, North Carolina State University	
	Genomic resources for canine cancer research Jessica Alföldi, Broad Institute of MIT and Harvard	
	Jessica Anolui, Dibau Institute of Mill and Haivard	
	Biology and informatics needs	
	Jeff Trent, TGEN	
12.15 nm	Group Discussion Lunch Break	
<u>12:15 pm</u> 1:00 pm	Session 3: Effectively integrating biomarkers into study designs	
	Moderator: Carl Barrett, AstraZeneca	
	Opportunities for preclinical evaluation of novel therapies	
	Timothy Fan, University of Illinois at Urbana-Champaign	
	PK assessment	
	Dan Gustafson, Colorado State University	
	PD and potential predictive biomarkers	
	Doug Thamm, Colorado State University	
	Group Discussion	
2:30 pm	Group Discussion   Session 4: Effectively integrating imaging technologies into study designs	
2.50 pm	<i>Moderator:</i> Peter Choyke, National Cancer Institute	
	Role of trials that include pets in the development of new imaging modalities	
	Peter Choyke, National Cancer Institute	

	MRI spectroscopy
	Mark Dewhirst, Duke University
	Group Discussion
3:30 pm	Break
3:45 pm	Session 5: Mechanisms for Comparative Oncology Trials
·	Moderator: Lou DeGennaro, Leukemia and Lymphoma Society
	Single-institution studies
	Cheryl London, Ohio State University
	Multi-institution studies
	Amy LeBlanc, National Cancer Institute
	Group Discussion
4:45 pm	Wrap up Day 1
5:15 pm	Reception – 3 <sup>rd</sup> Floor Atrium
	June 9th, 2015
7:30 am	Registration and Breakfast
8:00 am	Session 6: Addressing the needs of pet animals and their owners Moderator: Michael Lairmore, University of California—Davis
	Trial design and appropriate oversight
	David Vail, University of Wisconsin
	Best-practices for conduct of clinical trial for animal patients
	Rod Page, Colorado State University
	Patricia Olson, Independent Advisor on Animal Health/Welfare
	Group Discussion
9:45 am	Break
10:00 am	Session 7: The status of comparative oncology in drug development
	Moderator: Perry Nisen, Sanford-Burnham Research Institute
	Panelists:
	Anne Keane, Achaogen
	Wendy Levin, MEI Pharma
	Daniel Tumas, Gilead Sciences, Inc.
	John Leighton, Food and Drug Administration
	Group Discussion
11:30 pm	<b>Workshop Wrap Up</b> —Deborah Knapp, Purdue University & Len Lichtenfeld, American Cancer
12.00	Society
12:00 pm	Adjourn